ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1   The U.S. oral migraine drug market...

Read more

SAN DIEGO, February 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq:SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previouslyissued “Frequently Asked Questions” document under the...

Read more

Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for...

Read more

ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1   The acute migraine drug market size...

Read more